Bill Oxford/iStock via Getty Images
- Jefferies has initiated Prime Medicine (NASDAQ:PRME) with a bargain standing saying that the company's cistron editing level offers versatility, an vantage implicit different companies successful the space.
- The steadfast has a $25 terms people (~18% upside based connected Friday's close).
- Shares are down ~8% successful Monday greeting trading.
- Analyst Eun Yang said that the platform's versatility could perchance code ~90% of known familial mutations.
- Although quality investigating whitethorn not commencement until 2024-2025, carnal proof-of-concept information successful astir 2023, if positive, would bolster the platform, "potentially driving the shares higher fixed its wide applicability," she noted.
- Other things Prime Medicine (PRME) has going for it, according to Yang, are a wide pipeline and imaginable licensing/collaboration opportunities.
- Read wherefore Seeking Alpha contributor Bhavneesh Sharma calls Prime Medicine (PRME) a buy.
English (US)